Sign in
CompletedPhase 4

SePkLin Study: Pragmatic, Multicenter, Randomized, Controlled Clinical Trial in Patients with Sepsis to Evaluate the Safety and Efficacy of Personalized Pk/Pd Dosing Versus Standard Dosing of LINezolid.

Key facts

Who runs it
Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela
Where
Spain2 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 4
People taking part
692 people enrolled
Started
2 Apr 2024
Ended
4 Mar 2026
Type of study
Interventional
Record updated
2 August 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adult patients (18 years and older) receiving linezolid
  • Diagnosis of sepsis (SOFA scale ≥ 2 points or in the case of chronic organ dysfunction, increase of 2 points compared to the baseline score)
  • Patients have started antibiotic treatment with linezolid according to usual clinical practice

Who cannot take part

  • Known allergy or hypersensitivity to linezolid
  • Interruption of treatment before the first blood sample
  • Pregnant or nursing women
  • Patients will be excluded if they are already in any other intervention trials

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of the study is to demonstrate the superiority of personalized linezolid dosing based on PK/PD by evaluating the incidence of thrombocytopenia in both treatment groups.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
2 August 2024